$3.530
-0.293 (-8.31%)Zum Schluss
- High
- 3.825
- Open
- 3.800
- VWAP
- 3.63
- Vol
- 54.16K
- Mkt Cap
- —
- Low
- 3.530
- Amount
- 196.50K
- EV/EBITDA, TTM
- -1.20
BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.
AI analysis of BioStem Technologies, Inc. (BSEM)
holdBiostem Technologies, Inc. is currently a hold. The stock price is at $3.53, with a forward P/E ratio of 17.42, indicating potential for growth if the company can maintain its revenue trajectory. However, the stock has experienced a significant year-to-date decline of 19.77%, and recent earnings showed a reported EPS of -0.52, which is a risk factor.
Bewertungskennzahlen
BSEM FAQ — answered by Alphio AI
BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines. It operates in the Healthcare sector.
Biostem Technologies, Inc. is currently a hold. The stock price is at $3.53, with a forward P/E ratio of 17.42, indicating potential for growth if the company can maintain its revenue trajectory. However, the stock has experienced a significant year-to-date decline of 19.77%, and recent earnings showed a reported EPS of -0.52, which is a risk factor.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.